Bydureon BCise vs Victoza

exenatide extended-release (GLP-1 receptor agonist) vs liraglutide (GLP-1 receptor agonist) — a complete side-by-side comparison.

AstraZenecaNovo Nordisk

Bydureon BCise weight loss

2.3%

Victoza weight loss

3.2%

Bydureon BCise dosing

Once weekly

Victoza dosing

Once daily

Reviewed by Dr. Elena Vance, DOLast reviewed 4 sources cited

Quick Summary

Bydureon BCise (exenatide) and Victoza (liraglutide) are both glp-1 receptor agonists. In clinical trials, Victoza showed greater weight loss (3.2% vs 2.3%).

See the comparison table below for detailed side-by-side data.

Bydureon BCise vs Victoza: Full Comparison

FeatureBydureon BCise(exenatide extended-release)Victoza(liraglutide)
Active Ingredientexenatideliraglutide
Drug ClassGLP-1 receptor agonistGLP-1 receptor agonist
ManufacturerAstraZenecaNovo Nordisk
FDA Approved2012-01-272010-01-25
Approved Indications
  • Type 2 diabetes mellitus (adjunct to diet and exercise)
  • Type 2 diabetes mellitus (adjunct to diet and exercise)
  • Reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease
  • Type 2 diabetes in patients aged 10+ years
Routesubcutaneous injectionsubcutaneous injection
FrequencyOnce weeklyOnce daily
Starting Dose2 mg weekly0.6 mg daily
Maintenance Dose2 mg weekly1.2 mg or 1.8 mg daily
Max Dose2 mg weekly1.8 mg daily
Weight Loss (%)2.3%3.2%
A1C Reduction1.3%1.1%
Key TrialDURATION-1 (30 weeks)LEADER (188 weeks)
List Price$800-$950/month$950-$1,100/month
With Insurance$25-$100/month (varies by plan)$25-$150/month (varies by plan)
Savings CardLimited savings programs available$25/month (Novo Nordisk savings card, commercially insured)

Side Effects: Bydureon BCise vs Victoza

Side EffectBydureon BCiseVictoza
Nausea11%28%
Diarrhea9%17%
Injection site nodule10-17%Not reported
Headache8%9%
Vomiting4%11%
Constipation6%6%
Pancreatitis (rare)<1%<1%
Decreased appetiteNot reported9%
DyspepsiaNot reported7%

Severity scale: 1 (mild) to 5 (serious). Based on FDA prescribing information and clinical trial data.

Related Comparisons

Frequently Asked Questions

Sources & References

  1. Bydureon BCise FDA prescribing information
  2. Victoza FDA prescribing information
  3. Drucker DJ et al., Lancet 2008;372:1240-1250. FDA prescribing information.
  4. Marso SP et al., N Engl J Med 2016;375:311-322. FDA prescribing information.

This content is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions. See our full medical disclaimer.